Breaking News, Collaborations & Alliances

ABL Bio, GenScript Enter Biologics Partnership

ABL appoints GenScript as the exclusive supplier of CDMO services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GenScript Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), has entered into an agreement with ABL Bio Inc., a South Korean biotech company dedicated to therapeutics for immuno-oncology and neurodegenerative diseases. The parties have reached a partnership for two bispecific antibody programs.   According to the license agreement, GenScript will grant a sublicense to ABL Bio to use Ab (single-domain antibody), mAb (monoclonal antibody) targeting tumor ant...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters